Drug Profile
Factor VIIa-CTP - OPKO Health
Alternative Names: FVII-CTP - OPKO Health; MOD-5014; MOD-5017; OPK-88005Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator PROLOR Biotech
- Developer OPKO Health
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants
- Mechanism of Action Factor VIIa replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Haemophilia
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Haemophilia(In volunteers) in Israel (SC, Injection)
- 14 Sep 2021 LeaderMed Group and OPKO Health enters into joint venture for develop and commercialize factor VIIa-CTP in Asia, China, Hong Kong, Taiwan and Macau
- 14 Sep 2021 LeaderMed plans to seek fast regulatory approval for Haemophilia through a special national rare disease channel